Drug intelligence / Profile preview

KSI-102

Development stage: Unknown
Lead developer: Kodiak Sciences
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravitreal

Overview

KSI-102 is a bispecific antibody developed by Kodiak Sciences that simultaneously inhibits both tumor necrosis factor alpha (TNFα) and interleukin 6 (IL-6). It is designed for the treatment of ocular inflammatory diseases, including macular edema and uveitic macular edema. The drug leverages Kodiak’s Antibody Biopolymer Conjugate Drug (ABCD) platform technology, which aims to enhance drug delivery and durability in ocular tissues. By targeting both TNFα and IL-6, KSI-102 addresses key inflammatory pathways implicated in retinal diseases[1][2][4][9].

Targets

IL-6 (Interleukin 6)TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on KSI-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KSI-102.

Explore the full profile